Following a limited submission
AWMSG advice |
||||
| Status: Recommended | ||||
Insulin detemir (Levemir®) is recommended as an option for use within NHS Wales for the treatment of diabetes mellitus in children aged 1–5 years. (Insulin detemir (Levemir®) products are to be discontinued. See further information section) |
||||
|
||||
Medicine details |
||||
| Medicine name | insulin detemir (Levemir®) | |||
| Formulation | solution for injection | |||
| Reference number | 1427 | |||
| Indication | Treatment of diabetes mellitus in children aged 1-5 years |
|||
| Company | Novo Nordisk Ltd | |||
| BNF chapter | Endocrine system | |||
| Assessment type | Limited | |||
| Status | Recommended | |||
| Advice number | 3912 | |||
| NMG meeting date | 09/10/2012 | |||
| AWMSG meeting date | 14/11/2012 | |||
| Ratification by Welsh Government | 11/12/2012 | |||
| Date of issue | 13/12/2012 | |||
| Date of last review | 30/11/2016 | |||
| Further information
1) Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml pre-filled pens and Levemir® (insulin detemir) Penfill® 100units/ml solution for injection 3ml cartridges are being discontinued; stock is anticipated to be exhausted by the end of 2026. 2) Clinicians should not initiate new patients on any Levemir® product 3) Clinicians should begin implementing insulin switches for all existing Levemir® patients in line with PCDO Society guidelines. 4) a list of alternative insulins is available.
|
||||